Home > PF-06843195

molecules of the month

PF-06843195

oral PI3K_-selective kinase inhibitor prodrug

preclinical candidate for breast cancer

from mining of prior PI3K inh., SBDD, and opt.

J. Med. Chem., Dec. 24, 2020

Pfizer, San Diego, CA

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.